NASDAQ:ATRS - Antares Pharma Stock Price, Price Target & More

$2.33 -0.01 (-0.43 %)
(As of 04/20/2018 02:18 PM ET)
Previous Close$2.34
Today's Range$2.32 - $2.37
52-Week Range$1.58 - $4.09
Volume241,803 shs
Average Volume1.30 million shs
Market Capitalization$384.13 million
P/E Ratio-21.18
Dividend YieldN/A
Beta0.21

About Antares Pharma (NASDAQ:ATRS)

Antares Pharma logoAntares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs. The Company's subcutaneous injection technology platforms include VIBEX disposable pressure-assisted auto injectors, Vision reusable needle-free injectors and disposable multi-use pen injectors. The Company operates through drug delivery segment, which includes self-administered parenteral pharmaceutical products and technologies. The Company has developed OTREXUP (methotrexate) injection, which is a single dose, disposable auto injector.

Receive ATRS News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNASDAQ:ATRS
CUSIP03664210
Phone609-359-3020

Debt

Debt-to-Equity Ratio0.74%
Current Ratio3.53%
Quick Ratio2.94%

Price-To-Earnings

Trailing P/E Ratio-21.18
Forward P/E Ratio-33.29
P/E GrowthN/A

Sales & Book Value

Annual Sales$54.51 million
Price / Sales6.70
Cash FlowN/A
Price / CashN/A
Book Value$0.21 per share
Price / Book11.10

Profitability

EPS (Most Recent Fiscal Year)($0.11)
Net Income$-16,740,000.00
Net Margins-30.71%
Return on Equity-44.29%
Return on Assets-22.44%

Miscellaneous

Employees111
Outstanding Shares156,790,000

How to Become a New Pot Stock Millionaire

Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions

What is Antares Pharma's stock symbol?

Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS."

How were Antares Pharma's earnings last quarter?

Antares Pharma Inc (NASDAQ:ATRS) announced its earnings results on Tuesday, March, 13th. The specialty pharmaceutical company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.03) by $0.01. The specialty pharmaceutical company had revenue of $14 million for the quarter, compared to analyst estimates of $15.44 million. Antares Pharma had a negative net margin of 30.71% and a negative return on equity of 44.29%. The business's revenue was down 1.4% compared to the same quarter last year. View Antares Pharma's Earnings History.

What price target have analysts set for ATRS?

4 equities research analysts have issued 1 year target prices for Antares Pharma's shares. Their predictions range from $3.00 to $5.00. On average, they expect Antares Pharma's share price to reach $4.0750 in the next year. View Analyst Ratings for Antares Pharma.

Who are some of Antares Pharma's key competitors?

Who are Antares Pharma's key executives?

Antares Pharma's management team includes the folowing people:
  • Leonard S. Jacob M.D., Ph.D., Independent Chairman of the Board (Age 68)
  • Robert F. Apple CPA, President, Chief Executive Officer, Director (Age 51)
  • Fred M. Powell CPA, Chief Financial Officer, Senior Vice President, Principal Financial Officer and Principal Accounting Officer (Age 56)
  • Peter J. Graham, Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer (Age 50)
  • Thomas J. Garrity, Independent Director (Age 68)
  • Jacques Gonella Ph.D., Independent Director (Age 75)
  • Anton G. Gueth, Independent Director (Age 60)
  • Robert P. Roche Jr., Independent Director (Age 61)
  • Marvin S. Samson, Independent Director (Age 75)

Has Antares Pharma been receiving favorable news coverage?

Media coverage about ATRS stock has been trending somewhat positive on Friday, according to Accern. Accern rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Antares Pharma earned a news impact score of 0.05 on Accern's scale. They also assigned headlines about the specialty pharmaceutical company an impact score of 45.79 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.

How do I buy shares of Antares Pharma?

Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Antares Pharma's stock price today?

One share of ATRS stock can currently be purchased for approximately $2.32.

How big of a company is Antares Pharma?

Antares Pharma has a market capitalization of $384.13 million and generates $54.51 million in revenue each year. The specialty pharmaceutical company earns $-16,740,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Antares Pharma employs 111 workers across the globe.

How can I contact Antares Pharma?

Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected]


MarketBeat Community Rating for Antares Pharma (ATRS)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  189 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  319
MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote "Outperform" if you believe ATRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Antares Pharma (NASDAQ:ATRS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Antares Pharma in the last 12 months. Their average twelve-month price target is $4.0750, suggesting that the stock has a possible upside of 74.89%. The high price target for ATRS is $5.00 and the low price target for ATRS is $3.00. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.253.253.253.25
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $4.0750$4.0750$3.95$4.5750
Price Target Upside: 74.89% upside53.77% upside138.67% upside22.65% upside

Antares Pharma (NASDAQ:ATRS) Consensus Price Target History

Price Target History for Antares Pharma (NASDAQ:ATRS)

Antares Pharma (NASDAQ:ATRS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/27/2018HC WainwrightSet Price TargetBuy$4.00HighView Rating Details
10/23/2017Piper JaffraySet Price TargetBuy$3.00N/AView Rating Details
6/23/2017Chardan CapitalInitiated CoverageBuy$5.00HighView Rating Details
4/20/2017Raymond JamesInitiated CoverageStrong-Buy$4.30LowView Rating Details
5/10/2016Jefferies GroupReiterated RatingBuy$3.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Antares Pharma (NASDAQ:ATRS) Earnings History and Estimates Chart

Earnings by Quarter for Antares Pharma (NASDAQ:ATRS)

Antares Pharma (NASDAQ:ATRS) Earnings Estimates

2018 EPS Consensus Estimate: ($0.05)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.03)($0.03)($0.03)
Q2 20181($0.01)($0.01)($0.01)
Q3 20181($0.01)($0.01)($0.01)
Q4 20181$0.00$0.00$0.00

Antares Pharma (NASDAQ ATRS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2018Q4 2017($0.03)($0.02)$15.44 million$14.00 millionViewListenView Earnings Details
11/7/2017Q3 2017($0.03)($0.03)$14.01 million$15.10 millionViewN/AView Earnings Details
8/8/2017Q2 2017($0.03)($0.02)$12.99 million$13.42 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.04)($0.03)$12.10 million$12.01 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.04)($0.03)$12.77 million$14.20 millionViewN/AView Earnings Details
11/9/2016Q316($0.03)($0.04)$11.15 million$13.50 millionViewListenView Earnings Details
8/9/2016Q216($0.04)($0.04)$11.00 million$12.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.03)($0.05)$11.10 million$12.30 millionViewN/AView Earnings Details
3/8/2016Q415($0.03)($0.04)$12.53 million$11.80 millionViewN/AView Earnings Details
11/5/2015Q3 15($0.03)($0.04)$10.14 million$11.09 millionViewN/AView Earnings Details
8/10/2015Q215($0.03)($0.01)$10.93 million$14.40 millionViewListenView Earnings Details
5/11/2015Q115($0.04)($0.05)$9.22 million$8.30 millionViewListenView Earnings Details
3/12/2015Q414($0.05)($0.08)$8.50 million$8.40 millionViewN/AView Earnings Details
11/6/2014Q3 2014($0.07)($0.05)$6.92 million$6.57 millionViewN/AView Earnings Details
8/7/2014Q214($0.08)($0.07)$6.43 million$6.30 millionViewN/AView Earnings Details
5/9/2014Q114($0.04)($0.07)$6.17 million$5.20 millionViewN/AView Earnings Details
3/13/2014Q413($0.05)($0.04)$6.20 million$4.70 millionViewN/AView Earnings Details
11/6/2013Q313($0.04)($0.05)$5.86 million$5.50 millionViewN/AView Earnings Details
8/7/2013Q2 2013($0.03)($0.04)$5.82 million$5.84 millionViewN/AView Earnings Details
5/8/2013Q1 2013($0.03)($0.03)$5.12 million$4.50 millionViewN/AView Earnings Details
3/13/2013Q4 2012($0.03)($0.04)$5.36 million$5.50 millionViewN/AView Earnings Details
11/7/2012Q312($0.03)($0.03)$5.62 million$5.68 millionViewN/AView Earnings Details
8/8/2012($0.03)($0.03)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.01)($0.01)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.01)($0.02)ViewN/AView Earnings Details
5/9/2011Q1 2011($0.02)($0.02)ViewN/AView Earnings Details
3/14/2011Q4 2010($0.02)($0.02)ViewN/AView Earnings Details
11/10/2010Q3 2010($0.02)($0.02)ViewN/AView Earnings Details
8/12/2010Q2 2010($0.02)($0.02)ViewN/AView Earnings Details
5/13/2010Q1 2010($0.04)($0.02)ViewN/AView Earnings Details
3/23/2010Q4 2009($0.03)($0.03)ViewN/AView Earnings Details
11/9/2009Q3 2009($0.03)($0.04)ViewN/AView Earnings Details
8/13/2009Q2 2009($0.06)($0.03)ViewN/AView Earnings Details
5/13/2009Q1 2009($0.06)($0.04)ViewN/AView Earnings Details
3/25/2009Q4 2008($0.05)($0.04)ViewN/AView Earnings Details
11/13/2008Q3 2008($0.06)($0.05)ViewN/AView Earnings Details
8/14/2008Q2 2008($0.05)($0.05)ViewN/AView Earnings Details
5/15/2008Q1 2008($0.04)($0.05)ViewN/AView Earnings Details
3/26/2008Q4 2007($0.03)($0.05)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Antares Pharma (NASDAQ:ATRS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Antares Pharma (NASDAQ ATRS) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.60%
Institutional Ownership Percentage: 35.38%
Insider Trading History for Antares Pharma (NASDAQ:ATRS)
Institutional Ownership by Quarter for Antares Pharma (NASDAQ:ATRS)

Antares Pharma (NASDAQ ATRS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/9/2017Leonard S JacobDirectorSell230,000$4.05$931,500.00View SEC Filing  
10/3/2017Thomas J GarrityDirectorSell30,000$3.50$105,000.00View SEC Filing  
6/9/2017Fred M PowellInsiderBuy130,000$2.79$362,700.00331,434View SEC Filing  
4/5/2017Robert F AppleCEOSell40,000$3.00$120,000.00927,002View SEC Filing  
4/4/2017Leonard S JacobDirectorSell41,762$2.89$120,692.18238,885View SEC Filing  
4/4/2017Robert F AppleCEOSell37,000$3.00$111,000.00927,002View SEC Filing  
4/3/2017Leonard S JacobDirectorSell20,000$2.88$57,600.00238,885View SEC Filing  
3/31/2017Thomas J GarrityDirectorSell30,000$2.91$87,300.00190,213View SEC Filing  
12/9/2016Fred M PowellInsiderBuy100,000$2.03$203,000.00100,000View SEC Filing  
3/21/2016Peter J GrahamSVPBuy20,000$0.77$15,400.0020,000View SEC Filing  
3/18/2016James E FickenscherCFOBuy135,000$0.72$97,200.00270,216View SEC Filing  
3/18/2016Leonard S JacobDirectorBuy50,000$0.72$36,000.00218,885View SEC Filing  
3/18/2016Robert F AppleCEOBuy60,000$0.72$43,200.00517,164View SEC Filing  
9/30/2015James E FlynnMajor ShareholderSell249,998$1.69$422,496.62View SEC Filing  
9/29/2015James E FlynnMajor ShareholderSell225,048$1.82$409,587.36View SEC Filing  
9/28/2015James E FlynnMajor ShareholderSell1,353,483$1.81$2,449,804.23View SEC Filing  
8/24/2015Robert P Roche JrDirectorBuy5,000$1.77$8,850.0038,172View SEC Filing  
8/13/2015Robert P Roche JrDirectorBuy5,000$1.94$9,700.00View SEC Filing  
7/20/2015James E FlynnInsiderSell231,793$2.17$502,990.81View SEC Filing  
7/8/2015James E FlynnMajor ShareholderSell444,341$2.05$910,899.05View SEC Filing  
7/7/2015James E FlynnMajor ShareholderSell198,651$2.09$415,180.59View SEC Filing  
7/6/2015James E FlynnMajor ShareholderSell191,513$2.12$406,007.56View SEC Filing  
7/1/2015James E FlynnInsiderSell713,222$2.09$1,490,633.98View SEC Filing  
6/30/2015James E FlynnMajor ShareholderSell608,691$2.08$1,266,077.28View SEC Filing  
6/29/2015James E FlynnMajor ShareholderSell60,695$2.18$132,315.10View SEC Filing  
6/26/2015James E FlynnInsiderSell756,852$2.27$1,718,054.04View SEC Filing  
6/23/2015James E FlynnInsiderSell499,895$2.39$1,194,749.05View SEC Filing  
6/18/2015James E FlynnInsiderSell478,366$2.44$1,167,213.04View SEC Filing  
6/15/2015James E FlynnInsiderSell748,030$2.44$1,825,193.20View SEC Filing  
3/23/2015Leonard S JacobDirectorSell23,500$2.68$62,980.00View SEC Filing  
9/10/2014Eamonn P HobbsCEOBuy9,000$2.20$19,800.00View SEC Filing  
8/13/2014Robert P Roche JrDirectorBuy5,000$1.96$9,800.00View SEC Filing  
8/11/2014Marvin SamsonDirectorBuy25,000$2.00$50,000.00View SEC Filing  
12/9/2013Paul WottonCEOSell64,100$4.00$256,400.00708,734View SEC Filing  
10/14/2013Robert AppleCFOSell22,000$5.05$111,100.00368,918View SEC Filing  
9/3/2013Anton GuethDirectorSell25,000$4.42$110,500.00245,976View SEC Filing  
9/3/2013Paul WottonCEOSell35,000$4.41$154,350.00708,734View SEC Filing  
8/1/2013Anton GuethDirectorSell25,000$4.41$110,250.00View SEC Filing  
8/1/2013Paul K WottonCEOSell35,000$4.42$154,700.00View SEC Filing  
7/1/2013Anton GuethDirectorSell25,000$4.15$103,750.00View SEC Filing  
7/1/2013Paul K WottonCEOSell35,000$4.14$144,900.00View SEC Filing  
6/25/2013Eamonn P HobbsDirectorSell23,500$4.19$98,465.00View SEC Filing  
6/4/2013Robert F AppleCFOSell115,000$4.02$462,300.00View SEC Filing  
6/3/2013Anton GuethDirectorSell25,000$4.01$100,250.00View SEC Filing  
6/3/2013Kaushik J DaveEVPSell48,000$4.01$192,480.00View SEC Filing  
6/3/2013Paul K WottonCEOSell125,000$4.01$501,250.00View SEC Filing  
5/31/2013Thomas J GarrityDirectorSell13,000$4.08$53,040.00View SEC Filing  
5/17/2013Leonard S JacobDirectorSell17,000$4.00$68,000.00View SEC Filing  
11/16/2012Leonard S JacobDirectorBuy10,000$3.44$34,400.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Antares Pharma (NASDAQ ATRS) News Headlines

Source:
DateHeadline
Reviewing Antares Pharma (ATRS) and Interpace Diagnostics Gr (IDXG)Reviewing Antares Pharma (ATRS) and Interpace Diagnostics Gr (IDXG)
www.americanbankingnews.com - April 18 at 11:14 AM
Antares Pharma (ATRS) Raised to "Buy" at VetrAntares Pharma (ATRS) Raised to "Buy" at Vetr
www.americanbankingnews.com - April 17 at 4:47 PM
Antares Pharma (ATRS) Stock Rating Upgraded by VetrAntares Pharma (ATRS) Stock Rating Upgraded by Vetr
www.americanbankingnews.com - April 16 at 11:29 PM
Piper Jaffray Analysts Give Antares Pharma (ATRS) a $4.00 Price TargetPiper Jaffray Analysts Give Antares Pharma (ATRS) a $4.00 Price Target
www.americanbankingnews.com - April 15 at 11:43 PM
 Brokerages Anticipate Antares Pharma Inc (ATRS) Will Announce Quarterly Sales of $13.45 Million Brokerages Anticipate Antares Pharma Inc (ATRS) Will Announce Quarterly Sales of $13.45 Million
www.americanbankingnews.com - April 15 at 4:05 AM
Zacks: Brokerages Expect Antares Pharma Inc (ATRS) Will Announce Earnings of -$0.03 Per ShareZacks: Brokerages Expect Antares Pharma Inc (ATRS) Will Announce Earnings of -$0.03 Per Share
www.americanbankingnews.com - April 13 at 11:34 AM
Antares Pharma (ATRS) Raised to "Buy" at BidaskClubAntares Pharma (ATRS) Raised to "Buy" at BidaskClub
www.americanbankingnews.com - April 13 at 10:01 AM
Antares Pharma (ATRS) Given a $5.00 Price Target at HC WainwrightAntares Pharma (ATRS) Given a $5.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 11 at 11:52 PM
3 Things In Biotech, April 7: Lillys Surprising Liver Data, Antaress Retry Is Go, EyeGate Looks Toward The Future3 Things In Biotech, April 7: Lilly's Surprising Liver Data, Antares's Retry Is Go, EyeGate Looks Toward The Future
seekingalpha.com - April 8 at 9:25 AM
Antares Pharma (ATRS) Downgraded by BidaskClubAntares Pharma (ATRS) Downgraded by BidaskClub
www.americanbankingnews.com - April 5 at 10:26 AM
FDA accepts Antares Pharmas resubmitted Xyosted marketing application, action date September 29; shares up 10% premarketFDA accepts Antares Pharma's resubmitted Xyosted marketing application, action date September 29; shares up 10% premarket
seekingalpha.com - April 5 at 10:02 AM
Antares Pharma (ATRS) Says Complete Response Resubmission Accepted by FDA; PDUFA Date Set for September 29Antares Pharma (ATRS) Says Complete Response Resubmission Accepted by FDA; PDUFA Date Set for September 29
www.streetinsider.com - April 5 at 10:02 AM
BRIEF-Antares Pharma Provides Xyosted™ Regulatory UpdateBRIEF-Antares Pharma Provides Xyosted™ Regulatory Update
www.reuters.com - March 29 at 8:19 AM
Antares Pharma (ATRS) Receves Minutes from Type A Meeting with FDA in Connection with XYOSTED NDAAntares Pharma (ATRS) Receves Minutes from Type A Meeting with FDA in Connection with XYOSTED NDA
www.streetinsider.com - March 29 at 8:19 AM
$13.45 Million in Sales Expected for Antares Pharma Inc (ATRS) This Quarter$13.45 Million in Sales Expected for Antares Pharma Inc (ATRS) This Quarter
www.americanbankingnews.com - March 29 at 5:52 AM
Antares Pharma Inc (ATRS) Receives Consensus Rating of "Buy" from BrokeragesAntares Pharma Inc (ATRS) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 28 at 1:38 AM
ATRS: Xyosted Regulatory UpdateATRS: Xyosted Regulatory Update
finance.yahoo.com - March 27 at 5:19 PM
HC Wainwright Analysts Give Antares Pharma (ATRS) a $4.00 Price TargetHC Wainwright Analysts Give Antares Pharma (ATRS) a $4.00 Price Target
www.americanbankingnews.com - March 27 at 1:17 PM
Antares Pharma Inc (ATRS) Expected to Announce Earnings of -$0.03 Per ShareAntares Pharma Inc (ATRS) Expected to Announce Earnings of -$0.03 Per Share
www.americanbankingnews.com - March 27 at 1:14 PM
Antares Pharma to refile U.S. marketing application for Xyosted next quarter; shares up 1% premarketAntares Pharma to refile U.S. marketing application for Xyosted next quarter; shares up 1% premarket
seekingalpha.com - March 27 at 8:13 AM
ATRS: Multiple New Launches Fire Up 2018ATRS: Multiple New Launches Fire Up 2018
finance.yahoo.com - March 26 at 5:24 PM
Free Research Reports on These Medical Supplies Stocks -- Hill-Rom, NeuroMetrix, Akers Biosciences, and Antares ... - PR Newswire (press release)Free Research Reports on These Medical Supplies Stocks -- Hill-Rom, NeuroMetrix, Akers Biosciences, and Antares ... - PR Newswire (press release)
www.prnewswire.com - March 21 at 8:40 AM
Critical Comparison: Antares Pharma (ATRS) versus Tactile Systems Technology (TCMD)Critical Comparison: Antares Pharma (ATRS) versus Tactile Systems Technology (TCMD)
www.americanbankingnews.com - March 19 at 9:18 PM
Edited Transcript of ATRS earnings conference call or presentation 13-Mar-18 12:30pm GMTEdited Transcript of ATRS earnings conference call or presentation 13-Mar-18 12:30pm GMT
finance.yahoo.com - March 18 at 8:12 AM
FY2018 EPS Estimates for Antares Pharma Inc Raised by Jefferies Group (ATRS)FY2018 EPS Estimates for Antares Pharma Inc Raised by Jefferies Group (ATRS)
www.americanbankingnews.com - March 16 at 10:48 AM
Antares Pharma (ATRS) Downgraded to "Sell" at ValuEngineAntares Pharma (ATRS) Downgraded to "Sell" at ValuEngine
www.americanbankingnews.com - March 16 at 12:48 AM
Brokers Issue Forecasts for Antares Pharma Incs Q1 2018 Earnings (ATRS)Brokers Issue Forecasts for Antares Pharma Inc's Q1 2018 Earnings (ATRS)
www.americanbankingnews.com - March 15 at 7:25 AM
Antares Pharma (ATRS) Given a $4.00 Price Target at HC WainwrightAntares Pharma (ATRS) Given a $4.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 14 at 10:16 PM
Antares Pharma, Inc. to Host Earnings CallAntares Pharma, Inc. to Host Earnings Call
finance.yahoo.com - March 13 at 7:23 PM
Antares Pharma Reports Fourth Quarter and Full Year 2017 Operating and Financial ResultsAntares Pharma Reports Fourth Quarter and Full Year 2017 Operating and Financial Results
finance.yahoo.com - March 13 at 7:23 PM
Antares Pharma Provides Update Regarding the Cowen and Company 38th Annual Healthcare ConferenceAntares Pharma Provides Update Regarding the Cowen and Company 38th Annual Healthcare Conference
finance.yahoo.com - March 13 at 7:23 PM
Antares Pharma (ATRS) Posts  Earnings Results, Beats Estimates By $0.01 EPSAntares Pharma (ATRS) Posts Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - March 13 at 8:54 AM
Antares Pharma Reports Fourth Quarter and Full Year 2017 Operating and Financial Results - NasdaqAntares Pharma Reports Fourth Quarter and Full Year 2017 Operating and Financial Results - Nasdaq
www.nasdaq.com - March 13 at 8:17 AM
Antares Pharma Posts Narrower Loss In Q4 - Quick Facts - NasdaqAntares Pharma Posts Narrower Loss In Q4 - Quick Facts - Nasdaq
www.nasdaq.com - March 13 at 8:17 AM
Antares Pharma Inc (ATRS) Expected to Post Quarterly Sales of $14.96 MillionAntares Pharma Inc (ATRS) Expected to Post Quarterly Sales of $14.96 Million
www.americanbankingnews.com - March 12 at 7:54 AM
Antares Pharma (ATRS) Stock Rating Upgraded by ValuEngineAntares Pharma (ATRS) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - March 10 at 8:16 PM
Antares Pharma to Present at the Cowen and Company 38th Annual Healthcare Conference - GlobeNewswire (press release)Antares Pharma to Present at the Cowen and Company 38th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 10 at 8:16 AM
-$0.03 EPS Expected for Antares Pharma Inc (ATRS) This Quarter-$0.03 EPS Expected for Antares Pharma Inc (ATRS) This Quarter
www.americanbankingnews.com - March 10 at 5:08 AM
Antares Pharma to Present at the Cowen and Company 38th Annual Healthcare ConferenceAntares Pharma to Present at the Cowen and Company 38th Annual Healthcare Conference
feeds.benzinga.com - March 9 at 12:34 PM
Antares Pharma to Report Fourth Quarter and Full Year 2017 Financial and Operating ResultsAntares Pharma to Report Fourth Quarter and Full Year 2017 Financial and Operating Results
finance.yahoo.com - March 6 at 8:10 AM
Antares Pharma Inc (ATRS) Shares Bought by Broadfin Capital LLCAntares Pharma Inc (ATRS) Shares Bought by Broadfin Capital LLC
www.americanbankingnews.com - March 3 at 4:53 AM
Antares Pharma Inc (ATRS) Given Consensus Recommendation of "Buy" by BrokeragesAntares Pharma Inc (ATRS) Given Consensus Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - March 3 at 1:26 AM
Antares Pharma Inc (ATRS) Shares Sold by Fuller & Thaler Asset Management Inc.Antares Pharma Inc (ATRS) Shares Sold by Fuller & Thaler Asset Management Inc.
www.americanbankingnews.com - March 2 at 7:00 AM
Antares Pharma Announces Receipt of Second Installment from Sale of Zomajet™ Needle-Free Delivery System - GlobeNewswire (press release)Antares Pharma Announces Receipt of Second Installment from Sale of Zomajet™ Needle-Free Delivery System - GlobeNewswire (press release)
globenewswire.com - March 1 at 8:10 AM
Antares Pharma to Present at the Raymond James & Associates ... - GlobeNewswire (press release)Antares Pharma to Present at the Raymond James & Associates ... - GlobeNewswire (press release)
globenewswire.com - February 27 at 8:13 AM
Antares Pharma to Present at the Raymond James & Associates 39th Annual Institutional Investors ConferenceAntares Pharma to Present at the Raymond James & Associates 39th Annual Institutional Investors Conference
finance.yahoo.com - February 26 at 5:48 PM
JW Asset Management LLC Grows Holdings in Antares Pharma Inc (ATRS)JW Asset Management LLC Grows Holdings in Antares Pharma Inc (ATRS)
www.americanbankingnews.com - February 26 at 8:52 AM
Analyzing Antares Pharma (ATRS) and Given Imaging (GIVN)Analyzing Antares Pharma (ATRS) and Given Imaging (GIVN)
www.americanbankingnews.com - February 19 at 12:16 PM
Critical Contrast: DexCom (DXCM) and Antares Pharma (ATRS)Critical Contrast: DexCom (DXCM) and Antares Pharma (ATRS)
www.americanbankingnews.com - February 15 at 11:12 PM
Antares Pharma (ATRS) Reports FDA Approval of Partners Product Utilizing Our QuickShot Auto InjectorAntares Pharma (ATRS) Reports FDA Approval of Partner's Product Utilizing Our QuickShot Auto Injector
www.streetinsider.com - February 15 at 5:24 PM

SEC Filings

Antares Pharma (NASDAQ:ATRS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Antares Pharma (NASDAQ:ATRS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Antares Pharma (NASDAQ ATRS) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.